A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

NCT02712112 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Stromal Tumors (GISTs)

Interventions

DRUG: Imatinib Mesylate

Sponsor

Asan Medical Center